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PULMONOLOGY

Pulmonary Metastases of Basal Cell
Adenocarcinoma Presenting as Hemoptysis
Matthew DiMeglio, DO, MBA1, Mark Mallozzi, MD1, Prathna Kulandaisamy, MD2,
Julie Barta, MD2, Jennifer Johnson, MD, PhD3
1. Department of Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, PA.
2. Leonard and Jane Korman Respiratory Institute, Department of Pulmonary and Critical Care, Thomas Jefferson University Hospital,
Philadelphia, PA.
3. Department of Hematology and Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA.

Figure 1: Computed tomography (CT) chest revealing tumor invasion with intraluminal thrombus of the right superior pulmonic vein (A and B). Bronchoscopy revealing luminal
compromise (C) prompting tracheal stent placement (D). Positron emission tomography (PET) imaging ultimately showed increased tracer uptake concerning for malignancy (E).

INTRODUCTION
Basal Cell Adenocarcinoma (BCAC) is a rare malignancy,
only accounting for approximately 2% of all salivary
neoplasms1. Considered the malignant counterpart of
basal cell adenoma, it most commonly presents at 60
years of age without gender predilection. Sites of
involvement frequently includes the parotid gland, but
sites in the minor salivary glands, nasopharynx, buccal
mucosa, and tongue have also been reported2,3. Often
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regarded as an indolent malignancy, BCAC can
occasionally cause invasive disease and infrequently,
metastatic disease 2 . Among all solid tumors,
endobronchial metastases is quite a rare occurrence,
contributing to approximately 4% of endobronchial
biopsies4. Most common sites of metastases in BCAC
include cervical lymph nodes with sparse reports of
pulmonary, hepatic and cutaneous involvement5. We
present a case of endobronchial metastases from
BCAC of the base of the tongue.
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CASE PRESENTATION & OUTCOME

DISCUSSION & KEY POINTS

A 76-year-old male with a past medical history of BCAC
who underwent right tongue base excision with bilateral
neck dissection followed by adjuvant radiotherapy in
2018 and prostate cancer treated with radiotherapy
who presented with a one-day history of hemoptysis.
Two weeks prior to initial presentation, he underwent a
CT-guided lung biopsy for a right upper lobe nodule
that was nondiagnostic. There was concern that his
hemoptysis was related to his recent procedure, so he
was transferred to the academic medical center for
further evaluation.

The management of BCAC, as with all salivary gland
neoplasms, is particularly challenging due to the
phenotypic heterogeneity and low clinical incidence.
The most common strategy includes surgical resection
with adjuvant radiotherapy. While distant metastases is
an uncommon recurrence, local recurrence is quite
common despite tumor-free surgical margins with rates
of upward to 50%2. Chemotherapy has been found to be
of limited use, predominately in the setting of recurrent
or metastatic disease. Currently, there are no National
Comprehensive Care Network (NCCN) recommendations for specific regimens. The most common agents
include cisplatin, doxorubicin with either 5-fluorouracil
or cyclophosphamide. However, no regimen has
produced significant and reproducible improvements in
overall survival or disease-free survival6.

On presentation, the patient felt well overall and had
not experienced any additional occurrences of
hemoptysis. Vital signs were stable, and physical
examination was significant for decreased breath
sounds in the right lower lung field. CT chest with
contrast was performed and revealed an enlarging
mediastinal and right infra-hilar lymph node causing
severe stenosis of the bronchus intermedius, right
middle, and right lower lobe bronchus. Findings also
included direct invasion with an intraluminal thrombus
of the right superior pulmonic vein (Figures 1A, 1B).
On hospital day 2, patient underwent bronchoscopy
that revealed extensive endobronchial tumor
involvement of the bronchus intermedius resulting in
approximately 80% luminal compromise (Figure 1C).
Tumor debulking was performed as well as tracheal
stent placement (Figure 1D). Patient was discharged
following the procedure, and an outpatient PET scan
confirmed malignant involvement (Figure 1E).
Pathology of the endobronchial mass revealed a poorly
differentiated basaloid epithelial neoplasm that was
morphologically similar the prior tongue biopsy. Of
note, histology revealed an exceptionally high
proliferation index (Ki67 > 90%). Comprehensive
genomic profiling did not reveal any potential targeted
therapies. After discussion with the multidisciplinary
tumor board, the decision was made to pursue palliative
radiotherapy followed by pembrolizumab monotherapy.
The patient expired at home approximately two months
after initial diagnosis.

This case demonstrates several unique features. This
patient did not experience local recurrence, but rather
distant metastasis to a novel location. Also, this patient
featured an exceptionally high proliferation index,
indicating that BCAC has the potential for clinical
heterogeneity. Finally, this case highlights the need for
further research into the role of imaging surveillance
during remission.
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